Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Investing

European shares end lower on US rate, Trump jitters
Traders work in front of stock market displays.

Published : , on

By Shashwat Chauhan

(Reuters) -Europen shares slipped on Friday, weighed down by disappointing earnings, concerns about the impact of U.S. President-elect Donald Trump’s policies on global economies and businesses and a jump in Treasury yields.

The pan-European STOXX 600 index dropped 0.8%, trading just above a three-month low hit earlier this week.

U.S. stocks also lost ground after Federal Reserve Chair Jerome Powell said there was no need to rush interest rate cuts, pushing up U.S. Treasury yields and pressuring equities. [.N]

A week of indecision for stock markets is ending on a weaker note following Jerome Powell’s unexpected dialling back of dovish rhetoric,” said Chris Beauchamp, chief market analyst at online trading platform IG.

European equities came under renewed selling pressure this week as investors fretted over U.S.-China relations after Trump was expected to tap a China hawk to be his secretary of state.

European pharmaceutical companies fell on Friday after Trump picked Robert F. Kennedy Jr., an environmental activist who has spread misinformation on vaccines, to lead the Department of Health and Human Services.

Novo Nordisk fell 5.3%, while Sanofi shed 3.3% and GSK lost 3.9%.

The Swiss benchmark, which houses the bulk of European healthcare firms, declined 1.3%.

Downbeat earnings throughout the week also helped compound market losses.

The technology sub-index dropped 2.7%, with chipmaker ASML among top decliners, after U.S. firm Applied Materials forecast first-quarter revenue below estimates, a sign of sluggish demand for the chipmaking equipment outside of AI-powered chips.

Bavarian Nordic slid 17.4% after the Danish biotech firm posted a lower-than-expected core profit for the third quarter, 2025 orders below expectations.

Meanwhile, Russia’s Gazprom told Austria that it is suspending gas deliveries from Saturday, a gas flow monitoring platform reported, in a development that could signal the end of the last Russian gas supplies to Europe.

Austria is one of the few European countries still dependent on Russian gas as much of the rest of the continent has reduced imports following Moscow’s full-scale invasion of Ukraine in 2022.

Evotec jumped 21% after Halozyme Therapeutics said it has proposed to buy the German drug developer for about 2 billion euros ($2.11 billion).

Generali advanced 4.8% after Italy’s top insurer beat estimates for nine-month profits despite a 930 million euro hit from natural disasters.

($1 = 0.9471 euros)

(Reporting by Shashwat Chauhan and Sruthi Shankar in Bengaluru; Editing by Rashmi Aich and Elaine Hardcastle)

 

Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post